Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
14 Março 2023 - 9:11PM
Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the
acceptance of two oral and two poster presentations at the American
Association for Cancer Research (AACR) 2023 Annual Meeting, taking
place from April 14-19, 2023 in Orlando, Florida. Abstract titles,
presentation information and text, if provided by the meeting
organizers, are currently available on the AACR 2023 Annual Meeting
website.
Abstracts accepted for oral presentation
Title: TNG908, a brain-penetrant
MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical
glioblastoma modelsAbstract #: 3452Session
title: Novel Antitumor Agents and
TargetsPresenter: Kimberly Briggs, Ph.D.,
Associate Director, Tango TherapeuticsSession Date and
Time: April 17, 2023, 2:30-4:30 p.m. ET
TNG908 is brain penetrant in non-human primates, suggesting the
potential for clinical efficacy in MTAP-deleted glioblastoma (GBM).
Oral administration of TNG908 is efficacious in MTAP-deleted
xenograft models across histologies, including GBM. TNG908
treatment increased median survival by three-fold in a murine GBM
orthotopic model compared to controls. TNG908 is being studied in
an ongoing Phase 1/2 trial for patients with MTAP-deleted tumors,
including those with GBM.
Title: TNG260: A novel, orally active,
CoREST-selective deacetylase inhibitor for the treatment of
STK11-mutant cancers Session Title: New Drugs
on the Horizon Session: Part 3 Presenter:
Leanne Ahronian, Ph.D., Senior Scientist, Tango
Therapeutics Session Date and Time: April 17,
2023, 10:15-11:45 a.m. ET
Abstracts accepted for poster presentation
Title: Characterization of the clinical
development candidate TNG348 as a potent and selective inhibitor of
USP1 for the treatment of BRCA1/2mut cancersAbstract
#: 4968Format: Poster
PresentationSession Title: Novel Targets and
Pathways Session Date and Time: April 18, 2023,
1:30-5:00 p.m. ET
Title: TNG462 is a potential best-in-class
MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted
solid tumorsAbstract
#: 4970Format: Poster
PresentationSession Title: Novel Targets and
PathwaysSession Date and Time: April 18, 2023,
1:30-5:00 p.m. ET
About Tango TherapeuticsTango Therapeutics is a
clinical-stage biotechnology company dedicated to discovering novel
drug targets and delivering the next generation of precision
medicine for the treatment of cancer. Using an approach that starts
and ends with patients, Tango leverages the genetic principle of
synthetic lethality to discover and develop therapies that take aim
at critical targets in cancer. This includes expanding the universe
of precision oncology targets into novel areas such as tumor
suppressor gene loss and their contribution to the ability of
cancer cells to evade immune cell killing. For more information,
please visit www.tangotx.com.
Forward-Looking StatementsCertain statements in
this press release may be considered forward-looking statements.
Forward-looking statements generally relate to future events,
Tango’s future operating performance and goals, the anticipated
benefits of therapies and combination therapies (that include a
Tango pipeline product), expectations, beliefs and development
objectives for Tango’s product pipeline and clinical trials. In
some cases, you can identify forward-looking statements by
terminology such as “may”, “should”, “expect”, “intend”, “will”,
“goal”, “estimate”, “anticipate”, “believe”, “predict”, “potential”
or “continue”, or the negatives of these terms or variations of
them or similar terminology. For example, statements concerning the
following include or constitute forward-looking statements: TNG908
isbrain penetrant in non-human primates, suggesting the potential
for clinical efficacy in glioblastoma; TNG260 will be studied in a
phase 1/2 trial of STK11 mutant cancers in combination with a
checkpoint inhibitor; TNG462 is a potential best-in-class
MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted
solid tumors; the expected benefits of the Company's development
candidates and other product candidates; and the expected timing
of: (i) development candidate declaration for certain targets, (ii)
initiating IND-enabling studies; (iii) filing INDs; (iv) clinical
trial initiation and (v) disclosing initial and final clinical
trial results. Such forward-looking statements are subject to
risks, uncertainties, and other factors which could cause actual
results to differ materially from those expressed or implied by
such forward looking statements. These forward-looking statements
are based upon estimates and assumptions that, while considered
reasonable by Tango and its management, are inherently uncertain.
New risks and uncertainties may emerge from time to time, and it is
not possible to predict all risks and uncertainties. Factors that
may cause actual results to differ materially from current
expectations include, but are not limited to: Tango has limited
experience conducting clinical trials and may not be able to
commence the clinical trial (including opening clinical trial sites
and enrolling and dosing an adequate number of clinical trial
participants) when expected and may not generate results (including
final or initial safety and efficacy data) in the anticipated
timeframe (or at all); benefits of product candidates seen in
preclinical analyses may not be evident when tested in clinical
trials or when used in broader patient populations (if approved for
commercial sale); the benefits of Tango pipeline products,
development candidates and potential combination therapies that are
seen in pre-clinical experiments may not be present in clinical
trials or in use commercially or may not be safe and/or effective
in humans; Tango has a limited operating history and has not
generated any revenue to date from product sales, and may never
become profitable; other companies may be able to identify and
develop product candidates more quickly than the Company and
commercially introduce the product prior to the Company; the
Company’s proprietary discovery platform is novel and may not
identify any synthetic lethal targets for future development; the
Company may not be able to identify development candidates on the
schedule it anticipates due to technical, financial or other
reasons; the Company may not be able to file INDs for development
candidates on time, or at all, due to technical or financial
reasons or otherwise; the Company may utilize cash resources more
quickly than anticipated; Tango will need to raise capital in the
future and if we are unable to raise capital when needed or on
attractive terms, we would be forced to delay, scale back or
discontinue some of our development programs or future
commercialization efforts; we may be unable to advance our
preclinical development programs into and through the clinic for
safety or efficacy reasons or commercialize our product candidates
or we may experience significant delays in doing so as a result of
factors beyond Tango’s control; Tango’s approach to the discovery
and development of product candidates is novel and unproven, which
makes it difficult to predict the time, cost of development, and
likelihood of successfully developing any products; Tango may not
identify or discover additional product candidates or may expend
limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a
greater likelihood of success; our products candidates may cause
adverse or other undesirable side effects (or may not show
requisite efficacy) that could, among other things, delay or
prevent regulatory approval; our dependence on third parties for
conducting clinical trials and producing drug product; our ability
to obtain and maintain patent and other intellectual property
protection for our technology and product candidates or the scope
of intellectual property protection obtained is not sufficiently
broad; and delays and other impacts on product development and
clinical trials from the COVID-19 pandemic. Additional information
concerning risks, uncertainties and assumptions can be found in
Tango’s filings with the SEC, including the risk factors referenced
in Tango’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, as supplemented and/or modified by its most
recent Quarterly Report on Form 10-Q. You should not place undue
reliance on forward-looking statements in this presentation, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Tango
specifically disclaims any duty to update these forward-looking
statements.
Investor Contact:
Sam Martin/Andrew VulisArgot Partnerstango@argotpartners.com
Media Contact:
Amanda GalgaySVP, Corporate Communications, Tango
Therapeuticsmedia@tangotx.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024